Compounds for treating multiple myeloma
AssigneePurdue Pharma L.P.
InventorsKatarina Hilgier, Francisco Ibanez Lopez, Thomas Jorg Mehrling
Life of this patent
Estimating the term…
Abstract
The invention relates to tinostamustine for use in the treatment of multiple myeloma. Tinostamustine may cause side effects when administered to a patient, and it is desirable to minimise such effects. The present invention defines an improved treatment, wherein the dose of tinostamustine administered is varied based on the patient's platelet count.
Claims21
Tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of multiple myeloma in a patient, wherein the treatment involves:
- (a) determining whether the patient's initial platelet count is above or below a particular value;
- and
- (b) if the initial platelet count is above the particular value then administering a first amount of the tinostamustine or pharmaceutically acceptable salt thereof to the patient, and if the initial platelet count is below the particular value then administering a second amount of the tinostamustine or pharmaceutically acceptable salt thereof to the patient, wherein the first amount is greater than the second amount.
Tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of multiple myeloma in a patient, wherein the patient has a baseline platelet count of over 100×109/L and the tinostamustine or pharmaceutically acceptable salt thereof is administered at a dose of 55 mg/m2 or greater (for example 55-65 mg/m2 e.g. 60 mg/m2) based on free tinostamustine and the patient's body surface area.
Tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of multiple myeloma in a patient, wherein the patient has a baseline platelet count of 100×109/L or lower and the tinostamustine or pharmaceutically acceptable salt thereof is administered at a dose of 54 mg/m2 or lower (for example 45-54 mg/m2 e.g. 50 mg/m2) based on free tinostamustine and the patient's body surface area.
Tinostamustine or a pharmaceutically acceptable salt thereof for use according to any preceding claim, wherein the tinostamustine or pharmaceutically acceptable salt thereof is administered intravenously.
Tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of multiple myeloma in a patient, wherein the tinostamustine or pharmaceutically acceptable salt thereof is administered:
- intravenously;
- at a dose of from 20-100 mg/m2 based on free tinostamustine and the patient's body surface area, for example 55-65 mg/m2, 45-54 mg/m2 or 35-44 mg/m2 (e.g. 60 mg/m2;
- 50 mg/m2 or 40 mg/m2);
- and
- over a period of time which is 45-75 minutes, for example 50-70 minutes or 55-65 minutes e.g. 60 minutes.
Tinostamustine or a pharmaceutically acceptable salt thereof for use according to any preceding claim, wherein tinostamustine is in the form of a pharmaceutically acceptable salt which is the hydrochloride, hydrobromide, hydroiodide, sulfate, bisulfate, sulfamate, nitrate, phosphate, citrate, methanesulfonate, trifluoroacetate, glutamate, glucuronate, glutarate, malate, maleate, oxalate, succinate, fumarate, tartrate, tosylate, mandelate, salicylate, lactate, p-toluenesulfonate, naphthalenesulfonate or acetate.
Tinostamustine or a pharmaceutically acceptable salt thereof for use according to any preceding claim, wherein tinostamustine is in the form of the free compound i.e. is not in the form of a pharmaceutically acceptable salt.
Tinostamustine or a pharmaceutically acceptable salt thereof for use according to any preceding claim, wherein the multiple myeloma is relapsed or refractory multiple myeloma.
Tinostamustine or a pharmaceutically acceptable salt thereof for use according to any preceding claim, wherein the multiple myeloma is active myeloma, plasmacytoma, light chain myeloma or non-secretory myeloma.
Tinostamustine or a pharmaceutically acceptable salt thereof for use according to any preceding claim, wherein the tinostamustine or the pharmaceutically acceptable salt thereof is used as a monotherapy.
Tinostamustine or a pharmaceutically acceptable salt thereof for use according to any preceding claim, wherein the tinostamustine or the pharmaceutically acceptable salt thereof is used in combination with one or more other compounds or therapies.
Dependencies are inferred from the claim text.